Ophthalmic Formulations, Pelthos Therapeutics, Eye Pain
Summary
Pelthos Therapeutics Inc. filed US Patent Application US20260108500A1 on October 22, 2025, covering ophthalmic formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide or a pharmaceutically acceptable salt thereof. The application names four inventors: Eric D. Lang, Simon Paul Chandler, Deshou Jiang, and Richard Malamut. The formulations are directed to treatment of various eye conditions including pain.
“The present invention relates to ophthalmic formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide or a pharmaceutically acceptable salt thereof, to methods for preparation thereof, and uses thereof for treatment of various eye conditions (e.g., pain).”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 203 changes logged to date.
What changed
Pelthos Therapeutics Inc. has filed a patent application with the USPTO for ophthalmic formulations containing a specific thiazole-sulfonamide compound (2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide) and its pharmaceutically acceptable salts. The application covers both the formulation compositions and methods of preparing and using them. Competitors developing similar ophthalmic formulations for pain or other eye conditions should review this filing for potential freedom-to-operate concerns or prior art implications.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
OPHTHALMIC FORMULATIONS
Application US20260108500A1 Kind: A1 Apr 23, 2026
Assignee
PELTHOS THERAPEUTICS INC.
Inventors
Eric D. LANG, Simon Paul CHANDLER, Deshou JIANG, Richard MALAMUT
Abstract
The present invention relates to ophthalmic formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide or a pharmaceutically acceptable salt thereof, to methods for preparation thereof, and uses thereof for treatment of various eye conditions (e.g., pain).
CPC Classifications
A61K 31/426 A61K 9/06 A61K 47/10 A61K 47/26 A61K 47/38 A61P 27/04
Filing Date
2025-10-22
Application No.
19365360
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.